Skip to main content

Table 3 Mapping of the probabilities for the parametric estimation

From: Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy

Probability density estimation

Transition in the model

Gaining ≥22.5 letters

Gaining 2 health states

Gaining 7.5 to 22.5 letters

Gaining 1 health state

Gain/loss < 7.5 letters

No gain/loss

Losing 7.5 to 22.5 letters

Losing 1 health state

Losing ≥22.5 letters

Losing 2 health states